Better Health for All

Anebulo Pharmaceuticals' core business is developing ANEB-001 (selonabant) to treat acute cannabinoid intoxication (ACI) and unintentional cannabis poisoning, addressing a significant unmet medical need, particularly for children, for which no FDA-approved treatments currently exist.

This commitment to developing a potentially life-saving therapy for a critical health issue places its core health impact at a high positive tier. Across multiple Phase 1 and Phase 2 studies, involving 191 subjects who received selonabant, no severe adverse events were reported, and adverse events were consistently described as mild and transient. The company is prioritizing an intravenous formulation for pediatric patients, a vulnerable population, and the FDA has acknowledged this unmet need. However, the company's risk disclosures include forward-looking statements and general risk factors, rather than comprehensive, publicly available benefit and risk data. The company's R&D expenses were $4.3 million in fiscal year 2025, out of total operating expenses of $9.2 million, representing approximately 46.6% of operating expenses. The company also received a $1.9 million grant from NIDA for IV selonabant development. The company's product aims to mitigate the effects of cannabis-induced toxicity, which has seen emergency department visits rise from 1.1 million in 2014 to 1.8 million in 2021. The company is subject to stringent and evolving data privacy and security laws, including HIPAA and GDPR, with potential fines up to 4% of annual global revenue. The company holds three issued US patents for selonabant, with expected protection through 2040 and 2042, and multiple pending applications. The company acknowledges that efforts to educate the medical community may require significant resources and may not always be successful. The company conducts clinical trials under GCP regulations, requiring informed consent and IRB approval, and ensures risks are minimal relative to benefits.

Fair Money & Economic Opportunity

Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on drug development, specifically treatments for cannabinoid overdose and substance abuse.

The company's core business is not in financial services. Therefore, it does not offer lending or deposit services to consumers, provide consumer credit products, or engage in financial education programs. There is no evidence of the company generating or managing customer finance data, operating financial service access points, or having a direct impact on customer credit or savings outcomes. Consequently, all KPIs related to fair money and economic opportunity are scored as not applicable or having no direct impact, aligning with the company's business model outside the finance sector.

Fair Trade & Ethical Sourcing

Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company.

The provided documents, including SEC filings and codes of conduct, do not contain any quantitative or specific qualitative data related to fair trade or ethical sourcing metrics. There is no information regarding fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clause coverage in supplier contracts, share of spend on high-risk materials, or supplier diversity spend. Given the company's business model, the procurement or trading of physical commodities typically covered by fair-trade certifications is not applicable.

Honest & Fair Business

The company has a Whistleblower Policy, which includes procedures for the receipt, retention, and treatment of complaints regarding accounting, internal accounting controls, or auditing matters, and allows for confidential and anonymous submissions by employees.

A compliance hotline is available, and the policy explicitly prohibits retaliation for good faith reports of misconduct. However, three board members are noted to have material conflicts of interest due to their roles as founders or leaders of entities that are also company lenders. The company has a Code of Business Conduct and Ethics, amended on October 11, 2022, which prohibits illegal payments to government officials, referencing the U.S. Foreign Corrupt Practices Act, and addresses gratuities to U.S. government personnel. The company is subject to various regulations including the Sarbanes-Oxley Act and Dodd-Frank Act, which require effective disclosure and financial controls.

Kind to Animals

Anebulo Pharmaceuticals Inc. engages in animal testing.

Initial preclinical characterization of their lead product candidate, selonabant, involved non-animal methods such as established radioligand binding assays and in vitro testing across 90 binding assays and 19 enzyme and functional assays. However, the company also conducted efficacy studies using C57 mice, with 7 mice per group, to assess the reversal of THC-induced hypolocomotion. While non-animal assays cover early-stage characterization, animal testing is used for complex efficacy endpoints. The company does not explicitly state a formal animal testing policy, and a third-party source indicates the company engages in animal testing, suggesting routine non-essential testing may continue. The number of animals used annually is not disclosed, but the documented use of mice for efficacy studies places it in a negative tier.

Planet-Friendly Business

Anebulo Pharmaceuticals sources 42.6% of its energy from renewables for its research facilities.

The company has a waste diversion target of 18% year-over-year, but the actual diversion rate is not specified.

Safe & Smart Tech

The company has not experienced a cybersecurity incident that resulted in a material effect on its business strategy, results of operations, or financial condition as of February 10, 2026.

There are no documented incidents of unauthorized data use, and the company's privacy policy states personal information will only be used in accordance with the policy. The company collects data that could be used to identify users, such as log data, cookies, device information, usage information, and personal data like name and email address. It retains data only as long as necessary. The company is subject to extensive regulation by the FDA and other regulatory authorities, as well as healthcare laws like HIPAA, and federal consumer protection laws. It is also subject to data privacy and security obligations, including GDPR for EEA residents, and acknowledges potential fines up to 20 million Euros or 4% of annual global revenue under EU GDPR, and up to $7,500 per CCPA violation. The company's privacy policy outlines rights for EEA residents under GDPR, including access, erasure, rectification, objection to processing, restriction of processing, data portability, and withdrawal of consent, with a 30-day response time for GDPR requests. Users can contact info@anebulo.com to update their personal data.